Stocks Health care TXMD
NASDAQ · Health careTherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. brought in $3.3M of revenue over the twelve months to June 30, 2026, up 27.8% from a year earlier. It posted a net loss of $217K. At June 30, 2026 it held $9.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about TherapeuticsMD, Inc.
- Net worth
- TherapeuticsMD, Inc. has a market value (market cap) of $21.4M at the latest share price, and shareholders' equity of $27.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3M (+71.6% year on year), with a net loss of $569K. Over the 12 months to June 30, 2026: revenue $3.3M, net loss $217K.
- Cash flow
- In fiscal 2025 operations brought in $2.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- TherapeuticsMD, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What TherapeuticsMD, Inc. does
TherapeuticsMD, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TXMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3M | -$569K | -$0.05 | n/a |
| 2024 | $1.8M | -$2.2M | -$0.19 | n/a |
| 2023 | $1.3M | -$10.3M | -$0.99 | n/a |
| 2022 | $70M | $112M | $11.96 | n/a |
| 2021 | $2.6M | -$172.4M | -$21.66 | -$142.7M |
| 2020 | $64.9M | -$183.5M | -$33.75 | -$159.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TXMD ranks in Health care
Latest SEC filings
What TherapeuticsMD, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 8.7% to $869K versus the same quarter last year; diluted EPS $0.01 versus $0.05.
- August 11, 2026
- August 5, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 84% to $724K versus the same quarter last year; diluted EPS $0.01 versus -$0.06.
- May 12, 2026
- April 6, 2026Passive stake (5% or more) SCHEDULE 13G
- April 1, 2026Annual report (amended) 10-K/A · period to December 31, 2025Revenue rose 72% to $3M versus the prior year; diluted EPS -$0.05 versus -$0.19.
- April 1, 2026Late annual report notice NT 10-K
- March 30, 2026
- March 30, 2026Annual report 10-K · period to December 31, 2025Revenue rose 72% to $3M versus the prior year; diluted EPS -$0.05 versus -$0.19.
Insider trades
What the people running TherapeuticsMD, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| December 23, 2025 | Thompson Tommy GDirector | Bought | 8,400 | $14K |
Who owns TXMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Rubric Capital Management LP13D, may seek influence with 1 related filers | 25.73% | November 17, 2023 |
| Baselake Partners, LP13G, passive with 2 related filers | 6.8% | August 5, 2026 |
| Clearline Capital LP13G, passive with 2 related filers | 5.5% | February 12, 2025 |
Largest institutional holders
Insiders
1 insiders reported holding 23,179 shares in total, about $42.9K at the last price.
| Holder | Shares |
|---|---|
| Thompson Tommy GDirector | 23,179 |
Questions about TXMD
What does TherapeuticsMD, Inc. do?
TherapeuticsMD, Inc. is a company in the Health care sector, listed on NASDAQ as TXMD. Its shares trade on NASDAQ under the ticker TXMD.
What is TherapeuticsMD, Inc.'s net worth?
TherapeuticsMD, Inc. has a market value (market cap) of $21.4M at the latest share price, and shareholders' equity of $27.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is TherapeuticsMD, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $217K on revenue of $3.3M.
How much revenue does TherapeuticsMD, Inc. make?
Over the twelve months to June 30, 2026 TherapeuticsMD, Inc. reported revenue of $3.3M. That is 27.8% more than a year earlier.
When did TherapeuticsMD, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026.
When is TherapeuticsMD, Inc.'s next earnings report?
TherapeuticsMD, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TXMD with
Follow TXMD
Get an email when TherapeuticsMD, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values TherapeuticsMD, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.